Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M A WOOD

Showing results (91-100 of 108) with videos related to

Pageof 11
Sort By:
American Heart Journal|June 18, 1998
Suppression of inducible ventricular tachycardia by ibutilide in patients with coronary artery disease. Ibutilide InvestigatorsM A Wood, B S Stambler, K A Ellenbogen, et al.
The American Journal of Cardiology|January 1, 1997
Factors associated with elevated impedance with a nonthoracotomy defibrillation lead systemM C Kontos, K A Ellenbogen, M A Wood, et al.
The Annals of Thoracic Surgery|May 1, 1995
Clinical experience with nonthoracotomy cardioverter defibrillatorsJ S Lawton, K A Ellenbogen, M A Wood, et al.
The Annals of Thoracic Surgery|June 11, 1992
Implantation of cardioverter defibrillators in the post-sternotomy patientR J Damiano, A H Foster, K A Ellenbogen, et al.
Journal of the American College of Cardiology|March 15, 1995
Circadian pattern of ventricular tachyarrhythmias in patients with implantable cardioverter-defibrillatorsM A Wood, P M Simpson, W B London, et al.
Pacing and Clinical Electrophysiology : PACE|August 30, 2000
A prospective randomized-controlled trial of ventricular fibrillation detection time in a DDDR ventricular defibrillator. Ventak AV II DR Study InvestigatorsK A Ellenbogen, T Edel, S Moore, et al.
The American Journal of Cardiology|November 5, 1997
Are more complex implantable cardioverter defibrillators associated with an increased mortality? Lessons learned from clinical trialsK A Ellenbogen, A E Epstein, M A Wood, et al.
The American Journal of Cardiology|January 1, 1995
Safety and efficacy of intravenous diltiazem in atrial fibrillation or atrial flutterK A Ellenbogen, V C Dias, F P Cardello, et al.
Anales De Pediatria (Barcelona, Spain : 2003)|October 6, 2006
[The efficiency (cost-effectiveness) of palivizumab as prophylaxis against respiratory syncytial virus infection in premature infants with a gestational age of 32-35 weeks in Spain]P Lázaro y de Mercado, J Figueras Aloy, E Doménech Martínez, et al.
Journal of Medical Engineering & Technology|November 14, 1997
Rewards in practice from chrono-meta-analyses 'recycling' heart rate, ectopy, ischemia and blood pressure informationF Halberg, G Cornélissen, K Otsuka, et al.
Pageof 11

Showing results (91-100 of 108) with videos related to

Sort By:
Pageof 11
American Heart Journal|June 18, 1998
Suppression of inducible ventricular tachycardia by ibutilide in patients with coronary artery disease. Ibutilide InvestigatorsM A Wood, B S Stambler, K A Ellenbogen, et al.
The American Journal of Cardiology|January 1, 1997
Factors associated with elevated impedance with a nonthoracotomy defibrillation lead systemM C Kontos, K A Ellenbogen, M A Wood, et al.
The Annals of Thoracic Surgery|May 1, 1995
Clinical experience with nonthoracotomy cardioverter defibrillatorsJ S Lawton, K A Ellenbogen, M A Wood, et al.
The Annals of Thoracic Surgery|June 11, 1992
Implantation of cardioverter defibrillators in the post-sternotomy patientR J Damiano, A H Foster, K A Ellenbogen, et al.
Journal of the American College of Cardiology|March 15, 1995
Circadian pattern of ventricular tachyarrhythmias in patients with implantable cardioverter-defibrillatorsM A Wood, P M Simpson, W B London, et al.
Pacing and Clinical Electrophysiology : PACE|August 30, 2000
A prospective randomized-controlled trial of ventricular fibrillation detection time in a DDDR ventricular defibrillator. Ventak AV II DR Study InvestigatorsK A Ellenbogen, T Edel, S Moore, et al.
The American Journal of Cardiology|November 5, 1997
Are more complex implantable cardioverter defibrillators associated with an increased mortality? Lessons learned from clinical trialsK A Ellenbogen, A E Epstein, M A Wood, et al.
The American Journal of Cardiology|January 1, 1995
Safety and efficacy of intravenous diltiazem in atrial fibrillation or atrial flutterK A Ellenbogen, V C Dias, F P Cardello, et al.
Anales De Pediatria (Barcelona, Spain : 2003)|October 6, 2006
[The efficiency (cost-effectiveness) of palivizumab as prophylaxis against respiratory syncytial virus infection in premature infants with a gestational age of 32-35 weeks in Spain]P Lázaro y de Mercado, J Figueras Aloy, E Doménech Martínez, et al.
Journal of Medical Engineering & Technology|November 14, 1997
Rewards in practice from chrono-meta-analyses 'recycling' heart rate, ectopy, ischemia and blood pressure informationF Halberg, G Cornélissen, K Otsuka, et al.
Pageof 11